Our long-term therapy is based on a pancreatic proenzyme formulation that suppresses tumor recurrence and metastasis.
PRP, our lead candidate, controls cancer cell migration, inhibits tumor blood vessel formation and triggers the cell’s death.
Propanc commences investigational medicinal product manufacture of PRP for First-In-Human studies
Propanc successfully completes GLP-compliant 28-day repeat-dose toxicity study for PRP
80% of all cancers are solid tumors. We are initially targeting pancreatic, ovarian and colorectal tumors.
Oct 4, 2018
Stay informed about our latest news and updates